IBI310

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Hepatocellular CarcinomaResectable Hepatocellular CarcinomaSurufatinib

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

1

IBI310

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

12

Ibrance

Pfizer

Preclinical

13

Cysteine Hydrochloride

Novartis

Preclinical

14

Hepsera

Gilead

Preclinical

—5

Doptelet

AAkarx

Preclinical

16

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

17

Vermox

WWim Janssens

Preclinical

18

Valemetostat

Bristol-Myers Squibb

Preclinical

19

Alcohol

Astellas

Preclinical

—10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

1Show 20 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT03545971·53 enrolled

Gastric Cancer1 trial

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Unknown status·PPeking University·Phase 1/2·NCT04202601·80 enrolled

Hepatocellular Carcinoma1 trial

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

Not yet recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 2/3·NCT07490262·680 enrolled

Adult1 trial

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04868760·148 enrolled

Metastatic Colorectal Cancer1 trial

IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal Cancer

Terminated·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04258111·4 enrolled

7 more indications

Cervical Cancer1 trial

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT04590599·205 enrolled

Surufatinib1 trial

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)

Recruiting·PPeking University·Phase 2·NCT05165407·30 enrolled

Resistance1 trial

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04945421·30 enrolled

Lung Cancer1 trial

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05118334·30 enrolled

First-line Treatment1 trial

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04720716·344 enrolled

Biliary Tract Cancer1 trial

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Unknown status·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1/2·NCT05653180·20 enrolled

Resectable Hepatocellular Carcinoma1 trial

Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)

Not yet recruiting·SShanghai Zhongshan Hospital·Preclinical·NCT07714317·90 enrolled

Details

Drug Info

Related News